Allscripts (MDRX) Upgraded To Buy

Analysts at Jefferies & Co. have upgraded Allscripts Healthcare MDRX to Buy from the previous rating of Hold. The price target has also seen an upward revision of $4 to $25. Allscripts is poised to benefit from the push for adoption of electronic health records, as it has already penetrated the physician and hospital markets quite extensively. This coverage could prove a readymade advantage and takeoff point for Allscript. There is a very strong chance that earnings estimates will see an upward revision in the future. Moreover, there is a considerable opportunity for Allscripts to expand its margins in the coming years.